Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Current Deferred Revenue (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Current Deferred Revenue for 8 consecutive years, with $6.2 million as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue rose 3470.29% to $6.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Sep 2025, up 3470.29% year-over-year, with the annual reading at $3.0 million for FY2024, 75.43% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $6.2 million at Precision Biosciences, up from $6.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $53.1 million in Q1 2021, with the low at $175000.0 in Q3 2024.
  • Average Current Deferred Revenue over 5 years is $20.5 million, with a median of $19.7 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue tumbled 99.0% in 2024, then surged 3470.29% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $21.2 million in 2021, then skyrocketed by 117.44% to $46.2 million in 2022, then crashed by 73.95% to $12.0 million in 2023, then crashed by 75.43% to $3.0 million in 2024, then surged by 111.3% to $6.2 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $6.2 million, $6.0 million, and $5.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.